SANTA ROSA, Calif., April 27 /PRNewswire/ -- Endomatrix Inc. today announced the signing of a distribution agreement for its patented, dietary supplement Provasca with Actothil with GNC Corporation ("GNC"), Pittsburgh, PA. GNC will distribute the patented Provasca with Actothil in the United States and in international markets currently served by GNC.
It is estimated that less than 50 percent of people who experience a cardiovascular event have below-average cholesterol levels. Recent studies and scientific research have demonstrated that individuals with an independent risk factor, high levels of inflammation in their arteries, are more likely to become afflicted with cardiovascular disease than individuals with less vascular inflammation. These inflammation areas act as "landing zones" for LDL cholesterol and triglycerides. Actothil, the patented, all-natural active component of Provasca, assists the vascular system to maintain its normal, non-inflammatory state.
"Vascular inflammation and its blood-based biomarker C-reactive Protein ('CRP') are quickly becoming the leading indicators of future cardiovascular events," said Glenn Foley, President and Chief Executive Officer of Endomatrix. "Provasca with Actothil has been clinically proven to help the body's vascular system to maintain normal levels of C-reactive protein. We are very pleased to be working with GNC. They are committed to consumer education and to helping Endomatrix introduce this breakthrough platform to the US and selected international markets."
Provasca with Actothil will be highlighted at GNC's annual International Franchise Show, May 8, 9, and 10. GNC retail stores will start stocking Provasca with Actothil later that month.
Endomatrix Inc., based in Santa Rosa, California with subsidiaries in Europe and Asia, is focused on a product platform which addresses endothelial dysfunction, a disorder in the arteries which has been linked by physicians and clinical investigators to serious health conditions such as cardiovascular disease, diabetes, Alzheimer's and cancer. The company's current priority is cardiovascular health.